Positive Outlook for Unicycive Therapeutics Amidst Promising Developments and Financial Stability

Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Unicycive Therapeutics and keeping the price target at $22.00.

Swayampakula Ramakanth’s rating is based on several promising developments for Unicycive Therapeutics. The company is on track with its regulatory timeline for the resubmission of the New Drug Application (NDA) for its lead drug, oxylanthanum carbonate (OLC), which is intended for the treatment of hyperphosphatemia. The management has confirmed that they expect to resubmit the NDA by the end of the year, with an FDA decision anticipated in the first half of 2026. If approved, Unicycive plans to launch the drug commercially in the second half of 2026, with projected revenues reaching $611.2 million by 2030.
Additionally, Unicycive has demonstrated financial stability, ending the third quarter of 2025 with $42.7 million in cash and cash equivalents, which is sufficient to fund operations through the anticipated launch of OLC. The company has also secured agreements with investors that could provide additional funding upon FDA and TDAPA approvals. Ramakanth’s valuation model, which includes a risk-adjusted net present value analysis, supports a 12-month price target of $22 per share, reinforcing the Buy rating. Despite potential risks such as commercial and clinical challenges, the financial and strategic positioning of Unicycive underpins a positive outlook.

According to TipRanks, Ramakanth is a 5-star analyst with an average return of 22.5% and a 45.11% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Evaxion Biotech, Corcept Therapeutics, and Delcath Systems.

In another report released on October 30, Benchmark Co. also maintained a Buy rating on the stock with a $21.00 price target.